Adults with plaque psoriasis aged 65 years and older had similar responses to IL-17 and IL-23 inhibitors to that of younger adults.

A retrospective analysis of US medical records of people aged 65-95 years finds those with psoriasis on systemic therapies ...

Discover a study in which researchers examined three international cohorts of patients with moderate-to-severe psoriasis ...

For patients with psoriasis receiving biologic therapy, residual inflammation (RI), defined as increased inflammatory markers in blood, characterized by high-sensitivity C-reactive protein, despite ...

There is no cure for psoriasis and very little has changed in psoriasis treatments over the last 50 years. Moreover, currently available treatments are often fraught with uncomfortable side-effects, ...

Certain biologic therapies, such as ustekinumab, significantly effect hematological and lipid parameters in patients with psoriasis.

About 1 in 3 people with psoriasis who achieved clear skin with biologic drugs still had underlying inflammation that may contribute to conditions like obesity and heart disease, a new study suggests.

Starjemza (ustekinumab-hmny) was approved by the FDA this week as a biosimilar to Stelara. 2 A pair of clinical trials ...

THURSDAY, May 29, 2025 (HealthDay News) — Belly flab appears to be a stronger warning sign for psoriasis than fat located ...

Among 25 different measures of adiposity, abdominal fat was significantly associated with a risk for psoriasis. Among 25 ...

Researchers have found that central body fat, especially around the abdomen, is more strongly linked to psoriasis risk than ...

Researchers at King's College London have discovered a link between abdominal fat and a painful chronic inflammatory skin ...